Literature DB >> 32428375

Survival outcomes after surgical treatment of oral squamous cell carcinoma.

Annelies Weckx1, Kathrin J Grochau1, Andrea Grandoch1, Tim Backhaus1, Joachim E Zöller1, Matthias Kreppel1.   

Abstract

OBJECTIVE: To identify the clinicopathological parameters that influence survival in patients with oral squamous cell carcinoma, in order to allow for the development of individualized surveillance programmes and reduce the delay in diagnosis of recurrence.
MATERIALS AND METHODS: Retrospective chart review of 553 patients with a treatment-naïve primary oral squamous cell carcinoma, who underwent primarily curative intended surgery. Exclusion criteria were neoadjuvant radio(chemo)therapy, follow-up < 1 year, perioperative death, inoperable disease, synchronous multiple malignancies and inadequate information on clinicopathological parameters.
RESULTS: The clinicopathological factors that influence overall survival, disease-free survival and locoregional control were calculated. In the multivariate survival analysis, the occurrence of recurrence, presence of extracapsular spread, T- and N-classification were shown to be independent risk factors for overall survival.
CONCLUSION: The identification of these risk factors can lead to the development of individualized follow-up programmes based on risk stratification. This allows for the earliest possible diagnosis of relapse which is essential to offer the patient a realistic second treatment chance and to improve survival rates.
© 2020 The Authors. Oral Diseases published by John Wiley & Sons Ltd.

Entities:  

Keywords:  head and neck cancer; oral cancer; oral squamous cell carcinoma; recurrence; risk factors; survival

Mesh:

Year:  2020        PMID: 32428375     DOI: 10.1111/odi.13422

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  1 in total

1.  METTL3 suppresses anlotinib sensitivity by regulating m6A modification of FGFR3 in oral squamous cell carcinoma.

Authors:  Jie Chen; Shuai Li; Zhexun Huang; Congyuan Cao; Anxun Wang; Qianting He
Journal:  Cancer Cell Int       Date:  2022-09-27       Impact factor: 6.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.